FY2025 Earnings Forecast for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR) – Zacks Research lowered their FY2025 EPS estimates for Bruker in a report issued on Monday, February 10th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $2.73 per share for the year, down from their previous forecast of $2.76. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker’s Q4 2025 earnings at $0.92 EPS, Q4 2026 earnings at $0.84 EPS and FY2026 earnings at $3.32 EPS.

BRKR has been the subject of a number of other reports. TD Cowen dropped their target price on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a report on Wednesday, November 6th. The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective for the company in a report on Thursday, December 5th. Guggenheim reissued a “buy” rating on shares of Bruker in a research note on Friday, January 17th. UBS Group initiated coverage on Bruker in a research note on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price target for the company. Finally, Citigroup reduced their price objective on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $74.09.

Bruker Price Performance

Shares of Bruker stock opened at $50.65 on Wednesday. The company’s fifty day simple moving average is $58.04 and its two-hundred day simple moving average is $60.84. Bruker has a 12-month low of $48.07 and a 12-month high of $94.86. The firm has a market cap of $7.68 billion, a PE ratio of 24.35, a price-to-earnings-growth ratio of 3.81 and a beta of 1.16. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Monday, December 2nd were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date was Monday, December 2nd. Bruker’s dividend payout ratio (DPR) is presently 9.62%.

Insider Buying and Selling at Bruker

In related news, CEO Frank H. Laukien purchased 100,000 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were purchased at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the transaction, the chief executive officer now directly owns 38,439,563 shares in the company, valued at $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 28.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

Several hedge funds have recently added to or reduced their stakes in the stock. Retirement Systems of Alabama raised its position in shares of Bruker by 11.7% in the 3rd quarter. Retirement Systems of Alabama now owns 134,254 shares of the medical research company’s stock worth $9,272,000 after purchasing an additional 14,069 shares during the last quarter. Cerity Partners LLC raised its holdings in Bruker by 446.8% in the third quarter. Cerity Partners LLC now owns 27,998 shares of the medical research company’s stock worth $1,934,000 after buying an additional 22,878 shares during the last quarter. Merit Financial Group LLC purchased a new position in Bruker in the fourth quarter worth about $300,000. Brown Brothers Harriman & Co. lifted its stake in shares of Bruker by 39.9% in the third quarter. Brown Brothers Harriman & Co. now owns 602,144 shares of the medical research company’s stock worth $41,584,000 after buying an additional 171,806 shares in the last quarter. Finally, FMR LLC grew its holdings in shares of Bruker by 21.4% during the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock valued at $987,981,000 after buying an additional 2,521,904 shares during the last quarter. 79.52% of the stock is owned by institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.